Could a drug slow rare brain disease? new study uses Real-World data to find out
NCT ID NCT06529146
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether the drug troriluzole can slow the progression of spinocerebellar ataxia (SCA), a rare genetic disease that affects movement and balance. Researchers will compare 909 patients who took troriluzole for up to three years with similar patients who did not receive the drug, using data from natural history studies. The main goal is to see if treated patients have less worsening on a scale that measures coordination and daily function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
troriluzole (BHV-4157)
What this could lead to
If successful, this could show that troriluzole slows the worsening of movement problems in people with spinocerebellar ataxia over three years.
What could go wrong
This is a real-world data study, not a controlled trial, so results may be less reliable. The disease is rare and varies by genetic type, making it hard to prove effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINOCEREBELLAR ATAXIA TYPE 6 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biohaven
New Haven, Connecticut, 06510, United States